The antiobesity effects of centrally administered neuromedin u and neuromedin s are mediated predominantly by the neuromedin u receptor 2 (nmur2) Endocrinology
That's a real physiological role, but it's not the same as forcing fat loss
According to the TCGA database, The expression levels of SLC7A11 mRNA in Cervical cancer (CESC), Cholangiocarcinoma (CHOL), Colonic adenocarcinoma (COAD), Esophagus cancer (ESCA), Head and neck squamous cell carcinoma (HNSC), chromophobe kidney cell carcinoma (KICH), Clear cell carcinoma of kidney (KIRC), Papillary cell carcinoma of the kidney (KIRP), Liver cell carcinoma (LIHC), Lung adenocarcinoma (LUAD), Squamous cell carcinoma of the lung (LUSC), Adenocarcinoma of the pancreas (PAAD), Rectum adenocarcinoma (READ), Sarcoma (SARC), Cutaneous melanoma (SKCM), Stomach adenocarcinoma (STAD), and Endometrial carcinoma of the flesh (UCEC) were significantly higher than those in adjacent normal tissues

Metabolism & Elimination Limited characterization of specific metabolic pathways has been published for both peptides: CJC-1295 (NO DAC): Peptidase-mediated degradation represents primary metabolic pathway Four amino acid substitutions provide enhanced resistance to dipeptidyl peptidase-IV Metabolites and degradation products not fully characterized in published literature Clearance from circulation within hours despite sustained pharmacodynamic effects Ipamorelin: Clearance of 0.078 L/h/kg in human pharmacokinetic studies Rapid elimination from plasma following distribution phase Metabolic pathways likely involve proteolytic cleavage at peptide bonds No significant accumulation observed with repeated dosing in animal models A notable pharmacokinetic-pharmacodynamic disconnect exists: despite relatively short plasma half-lives (30 minutes to 2 hours), growth hormone secretory effects persist for 6+ hours, suggesting either active metabolites, tissue retention, or persistent receptor signaling cascade activation
